BRIEF-Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline
Reuters
Yesterday
BRIEF-Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline
ENSOMA ANNOUNCES $53 MILLION FINANCING TO SUPPORT KEY CLINICAL MILESTONES FOR EN-374 AND CONTINUED DEVELOPMENT OF IN VIVO HEMATOPOIETIC STEM CELL ENGINEERING PIPELINE
ENSOMA : INVESTORS INCLUDE GILEAD WHICH HAS ALSO APPOINTED AN EXECUTIVE TO ENSOMA BOARD OF DIRECTORS AS PART OF ITS INVESTMENT
Source text: ID:nBw63hfHZa
Further company coverage: GILD.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.